208 related articles for article (PubMed ID: 34903601)
1. Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma.
Carrabotta M; Laginestra MA; Durante G; Mancarella C; Landuzzi L; Parra A; Ruzzi F; Toracchio L; De Feo A; Giusti V; Pasello M; Righi A; Lollini PL; Palmerini E; Donati DM; Manara MC; Scotlandi K
Cancer Res; 2022 Feb; 82(4):708-720. PubMed ID: 34903601
[TBL] [Abstract][Full Text] [Related]
2. Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma.
Lin YK; Wu W; Ponce RK; Kim JW; Okimoto RA
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20776-20784. PubMed ID: 32788348
[TBL] [Abstract][Full Text] [Related]
3.
Yoshimoto T; Tanaka M; Homme M; Yamazaki Y; Takazawa Y; Antonescu CR; Nakamura T
Cancer Res; 2017 Jun; 77(11):2927-2937. PubMed ID: 28404587
[No Abstract] [Full Text] [Related]
4. Spontaneous expression of the CIC::DUX4 fusion oncoprotein from a conditional allele potently drives sarcoma formation in genetically engineered mice.
Hendrickson PG; Oristian KM; Browne MR; Luo L; Ma Y; Cardona DM; Nash JO; Ballester PL; Davidson S; Shlien A; Linardic CM; Kirsch DG
Oncogene; 2024 Apr; 43(16):1223-1230. PubMed ID: 38413794
[TBL] [Abstract][Full Text] [Related]
5. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
Loganathan SN; Tang N; Holler AE; Wang N; Wang J
Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
[TBL] [Abstract][Full Text] [Related]
6. Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines.
Oyama R; Takahashi M; Yoshida A; Sakumoto M; Takai Y; Kito F; Shiozawa K; Qiao Z; Arai Y; Shibata T; Araki Y; Endo M; Kawai A; Kondo T
Sci Rep; 2017 Jul; 7(1):4712. PubMed ID: 28680140
[TBL] [Abstract][Full Text] [Related]
7. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.
Okimoto RA; Wu W; Nanjo S; Olivas V; Lin YK; Ponce RK; Oyama R; Kondo T; Bivona TG
J Clin Invest; 2019 Jul; 129(8):3401-3406. PubMed ID: 31329165
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features of five cases of CIC::DUX4 positive sarcomas, including literature review.
Rekhi B; Rumdee R; Shetty O
Ann Diagn Pathol; 2023 Aug; 65():152153. PubMed ID: 37167753
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas.
Italiano A; Sung YS; Zhang L; Singer S; Maki RG; Coindre JM; Antonescu CR
Genes Chromosomes Cancer; 2012 Mar; 51(3):207-18. PubMed ID: 22072439
[TBL] [Abstract][Full Text] [Related]
10. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract][Full Text] [Related]
11. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
12. The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas.
Graham C; Chilton-MacNeill S; Zielenska M; Somers GR
Hum Pathol; 2012 Feb; 43(2):180-9. PubMed ID: 21813156
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma.
Yoshimatsu Y; Noguchi R; Tsuchiya R; Kito F; Sei A; Sugaya J; Nakagawa M; Yoshida A; Iwata S; Kawai A; Kondo T
Hum Cell; 2020 Apr; 33(2):427-436. PubMed ID: 31898195
[TBL] [Abstract][Full Text] [Related]
14. Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities.
Specht K; Sung YS; Zhang L; Richter GH; Fletcher CD; Antonescu CR
Genes Chromosomes Cancer; 2014 Jul; 53(7):622-33. PubMed ID: 24723486
[TBL] [Abstract][Full Text] [Related]
15. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
Ruicci KM; Meens J; Sun RX; Rizzo G; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Boutros PC; Ailles L; Nichols AC
Int J Cancer; 2019 Oct; 145(8):2100-2106. PubMed ID: 30468243
[TBL] [Abstract][Full Text] [Related]
17. Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma group.
Brahmi M; Gaspar N; Gantzer J; Toulmonde M; Boudou-Rouquette P; Bompas E; Firmin N; Valentin T; Cancel M; Duffaud F; Bertucci F; Perrin C; Dufresne A; Marec-Bérard P; Jean-Denis M; Ray-Coquard I; Le Loarer F; Pierron G; Tirode F; Blay JY; Watson S
Cancer Med; 2023 Apr; 12(7):7801-7807. PubMed ID: 36537582
[TBL] [Abstract][Full Text] [Related]
18. Undifferentiated round cell sarcomas with CIC-DUX4 gene fusion: expanding the clinical spectrum.
Brčić I; Brodowicz T; Cerroni L; Kashofer K; Serbanescu GL; Kasseroler MT; Amann G; Scheipl S; Szkandera J; Leithner A; Liegl-Atzwanger B
Pathology; 2020 Feb; 52(2):236-242. PubMed ID: 31870501
[TBL] [Abstract][Full Text] [Related]
19. CIC-DUX4 sarcomas.
Brahmi M; Vanacker H; Macagno N; Tirode F; Dufresne A
Curr Opin Oncol; 2022 Jul; 34(4):342-347. PubMed ID: 35730520
[TBL] [Abstract][Full Text] [Related]
20. Superficial sarcomas with CIC rearrangement are aggressive neoplasms: A series of eight cases.
Ko JS; Marusic Z; Azzato EM; Farkas DH; Van Arnam J; Seiwerth S; Fritchie K; Patel RM; Rubin BP; Billings SD
J Cutan Pathol; 2020 Jun; 47(6):509-516. PubMed ID: 32026485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
